Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
• Limited effective therapeutic options exist for advanced NSCLC.
• The role of specific genetic alterations, such as Onc-p53 alleles, in NSCLC progression is an area of active research.

Purpose of the Study:

• To investigate the efficacy of a novel combination therapy for NSCLC.
• To determine if this combination therapy represents a precision medicine approach for NSCLC.
• To evaluate the effectiveness of the therapy in NSCLC cells and tumors harboring Onc-p53 alleles.

Main Methods:

• Utilized a combination of a proteasome inhibitor, a BH3-mimetic, and standard chemotherapy.
• Tested the therapeutic combination in NSCLC cell lines and patient-derived tumor models.
• Assessed treatment response in models with specific Onc-p53 genetic profiles.

Main Results:

• The combination therapy demonstrated significant activity in NSCLC cells.
• Tumor growth was effectively inhibited by the combination regimen in preclinical models.
• The therapy showed particular efficacy in NSCLC expressing Onc-p53 alleles, indicating a precision medicine effect.

Conclusions:

• Combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active treatment strategy for NSCLC.
• This regimen functions as a precision therapy for NSCLC patients with Onc-p53 alterations.
• Further clinical investigation is warranted to translate these findings into patient care.